Macrogenics (MGNX) Other Non-Current Assets (2012 - 2026)
Macrogenics (MGNX) reported Other Non-Current Assets of $1.4 million for Q1 2026, down 7.65% year-over-year from $1.5 million in Q1 2025, and down 0.65% quarter-over-quarter from $1.4 million in Q4 2025.
Macrogenics (MGNX) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Other Non-Current Assets data on file, last reported at $1.4 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $1.4 million, down 7.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 7.65% YoY), and the FY2025 annual result was $1.4 million, down 10.99% from the prior year.
- Other Non-Current Assets slipped to $1.4 million in Q1 2026 per MGNX's latest filing, from $1.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $17.2 million in Q1 2022 and troughed at $1.2 million in Q1 2024.
- A 5-year average of $4.0 million and a median of $1.4 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets slumped 91.99% in 2023, then advanced 25.74% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $1.4 million in 2022, then grew by 0.58% to $1.4 million in 2023, then climbed by 12.27% to $1.6 million in 2024, then retreated by 10.99% to $1.4 million in 2025, then declined by 0.65% to $1.4 million in 2026.
- Business Quant data shows MGNX's Other Non-Current Assets at $1.4 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | 1.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.38 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 15.54 Mn |
| Jun 30, 2022 | 16.39 Mn |
| Mar 31, 2022 | 17.21 Mn |
| Dec 31, 2021 | 1.40 Mn |
| Sep 30, 2021 | 18.78 Mn |
| Jun 30, 2021 | 19.52 Mn |